Overview


According to FutureWise analysis the europe platelet rich plasma market in 2023 was US$ 0.11 billion, and is expected to reach US$ 0.36 billion by 2031 at a CAGR of 15.82%. The increasing adoption of regenerative therapies in fields such as orthopedics, aesthetics, and sports medicine is contributing to significant growth in this sector. A growing awareness of the minimally invasive nature of platelet-rich plasma (PRP) therapy, combined with its effectiveness in promoting tissue healing, is driving demand in several key European countries, including Germany, France, and the UK.

Platelet-rich plasma, also known as autologous conditioned plasma, is a concentrate of platelet-rich plasma protein derived from whole blood, centrifuged to remove red blood cells. Europe platelet rich plasma market includes market size for platelet-rich plasma systems and platelet-rich plasma kits. The market report includes Europe platelet-rich plasma market value analysis by product type, applications, end user and country. PRP Systems and Platelet-rich plasma systems included in this report are centrifuge systems specifically for separation of platelet-rich plasma and platelet poor plasma from autologous blood samples drawn at the point-of-care facility. Other centrifuge systems which have application in other cellular therapies and preparation of substances derived from body fluids are excluded from the scope of this report

Examples of PRP systems included in this report are GPS® III Platelet Concentration System (Zimmer Biomet), The Arthrex ACP® Double Syringe System (Arthrex Inc), Arthrex Angel® cPRP Processing System (Arthrex Inc.) etc. among others PRP kits considered in this segment of the report include PRP preparation kits and PRP harvest kits. PRP Kit that makes Platelet-Rich Plasma extractions simple and cost-efficient PRP preparation and harvest kits generally include PRP Tubes, Re-Suspension Tube, injectors, needles, phlebotomy sets etc. PRP kits are made available to end users through three prominent sales channels. Sales channels included in this report are Direct Sales Channels, Distributor Sale Channels, and Others (group purchasing organisations, wholesalers, pharmacists, etc.)

  • Terumo BCT
  • Zimmer Biomet
  • NeoGenesis Co. Ltd
  • Glofinn oy Overview
  • T Biotechnology (T Lab)
  • Regen Lab SA, SDD Medical Group Ltd Overview
  • IntraVita International Limited Overview
  • Exactech Inc.
  • Arthrex Inc.
  • Biotechnology Institute (bti)

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Europe Platelet Rich Plasma Market:

Terumo BCT

In October 2024, initiated a decade-long partnership with the Sanquin Blood Supply Foundation in the Netherlands to implement the automated Reveos™ Blood Processing System. This initiative seeks to enhance the efficiency of plasma and platelet processing, ultimately reinforcing the PRP production framework across Europe.

Arthrex Inc.

  • In April 2025, the ACP Max™ PRP System was introduced, featuring a larger blood draw and an innovative double-spin, double-syringe design that provides elevated platelet concentrations and an increased amount of growth factors per dose, establishing it as a next-generation PRP device in the fields of orthopedics and regenerative medicine.
  • January 2024: Showcased the practical application of ACP Max utilizing PRP with low neutrophil content, emphasizing its commitment to precision and enhanced patient results.

T Biotechnology (T Lab)

By early 2025, the T-Lab was acknowledged as the top PRP system at the IMCAS World Congress, following an impartial assessment of seven worldwide systems. T-Lab distinguished itself with an outstanding platelet count of 4.6 billion platelets and a recovery rate of 90.1%—providing substantial confirmation of its effectiveness in Europe.

By Product Type

  • Instruments
  • Kits
    • Kit By Type
      • Pure Platelet-Rich Plasma (P-PRP)
      • Leukocyte-Rich Platelet-Rich Plasma (L-PRP)
      • Leukocyte-Platelet-Rich Fibrin (L-PRF)
      • Pure Platelet-Rich Fibrin (P-PRF)
    • Kit By Origin
      • Autologous Platelet-Rich Plasma
      • Homologous Platelet-Rich Plasma
      • Allogeneic Platelet-Rich Plasm

By Application

  • Cosmetic/Aesthetic/Hair Fall Treatment
  • Orthopedics/Rehabilitation medicine
  • Dentistry
  • Ophthalmology
  • Research and Development
  • Veterinary

By End Users

  • Physician's office/Private Practice/Veterinary Clinics
  • Hospitals
  • Orthopedic Clinics
  • Cosmetic/dermatology/Trichology Clinics
  • Academic and Research Institutes

By Region

  •  Germany
  •  U.K
  •  France
  •  Italy
  •  Spain
  •  Russia
  •  Poland
  •  Rest of Europe

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on Europe Platelet Rich Plasma Market By Product, By Application, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and overall market
  • To predict market size, in five key regions (along with countries)—Germany, U.K, France, Italy, Spain, Russia, Poland, Rest of Europe
  • To record evaluate and competitive landscape mapping-product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Europe Platelet Rich Plasma Market Variables, Trends and Scope
    •          1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Europe Platelet Rich Plasma Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Europe Platelet Rich Plasma Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Europe Platelet Rich Plasma Market, By Product Type Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Instruments
        2. Kits
         2.1. Kit By Type
          2.1.1. Pure Platelet-Rich Plasma (P-PRP)
          2.1.2. Leukocyte-Rich Platelet-Rich Plasma (L-PRP)
          2.1.3. Leukocyte-Platelet-Rich Fibrin (L-PRF)
          2.1.4. Pure Platelet-Rich Fibrin (P-PRF)
         2.2. Kit By Origin
          2.2.1. Autologous Platelet-Rich Plasma
          2.2.2. Homologus Platelet-Rich Plasma
          2.2.3. Allogeneic Platelet-Rich Plasma

  • 8.   Europe Platelet Rich Plasma Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Cosmetic/Aesthetic/Hair Fall Treatment
        2. Orthopedics/Rehabilitation medicine
        3. Dentistry
        4. Ophthalmology
        5. Research and Development
        6. Veterinary

  • 9.   Europe Platelet Rich Plasma Market, By End Users Historical Analysis and Forecast 2025-2033 (USD Million)
    •     1. Physician's office/Private Practice/Veterinary Clinics
        2. Hospitals
        3. Orthopedic Clinics
        4. Cosmetic/dermatology/Trichology Clinics
        5. Academic and Research Institutes

  • 10.  Europe Platelet Rich Plasma Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 11.   Market Share Analysis and Competitive Landscape
    •   1. Europe Landscape - Key Players, Revenue and Presence
        2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Europe Emerging Companies
        4. Europe - Market Share Analysis and Key Regional Player
        5. Europe Key Player - Growth Matrix

  • 12.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Terumo BCT
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Zimmer Biomet
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. NeoGenesis Co. Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Glofinn oy Overview
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. T Biotechnology (T Lab),
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Regen Lab SA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. SDD Medical Group Ltd Overview
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. IntraVita International Limited Overview
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Exactech Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Arthrex Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Biotechnology Institute (bti
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 13.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 14.   FutureWise SME Key Takeaway Points for Client

Related Market

Platelet Rich Plasma Market

Read More

Plasma Therapy Market

Read More

Plasma Derived Medicine Market

Read More
Partner

Our Clients